Myelodysplastic Syndrome (MDS)Symptoms, Doctors, Treatments, Advances & More
Myelodysplastic Syndrome (MDS) Overview
Learn About Myelodysplastic Syndrome (MDS)
Myelodysplastic syndrome is a group of disorders in which the blood cells produced in the bone marrow do not mature into healthy cells. This leaves you with fewer healthy blood cells in your body. The blood cells that have matured may not function properly.
Myelodysplastic syndrome (MDS) is a form of cancer. In about a third of people, MDS may develop into acute myeloid leukemia (AML).
Myeloid malignancy; Myelodysplastic syndrome; MDS; Preleukemia; Smoldering leukemia; Refractory anemia; Refractory cytopenia
Stem cells in bone marrow form different types of blood cells. With MDS, the DNA in stem cells becomes damaged. Because the DNA is damaged, the stem cells cannot produce healthy blood cells.
The exact cause of MDS is not known. For most cases, there is no known cause.
Risk factors for MDS include:
- Certain genetic conditions
- Exposure to environmental or industrial chemicals, fertilizers, pesticides, solvents, or heavy metals
- Smoking
Prior cancer treatment increases the risk for MDS. This is called secondary or treatment-related MDS.
- Certain chemotherapy medicines increase the chance of developing MDS. This is a major risk factor.
- Radiation therapy, when used with chemotherapy, increases the risk for MDS even more.
- People who have stem cell transplants may develop MDS because they also receive high doses of chemotherapy.
MDS usually occurs in adults age 60 years and older. It is more common in men.
Early stage MDS often has no symptoms. MDS is often discovered during other blood tests.
People with very low blood counts often experience symptoms. Symptoms depend on the type of blood cell affected, and they include:
- Weakness or tiredness due to anemia
- Shortness of breath
- Easy bruising and bleeding
- Small red or purple pinpoint dots under the skin caused by bleeding
- Frequent infections and fever
Your treatment will depend on several factors:
- Whether you are low-risk or high-risk
- The type of MDS you have
- Your age, health, and other conditions you may have, such as diabetes or heart disease
The goal of MDS treatment is to prevent leukemia from developing and to prevent problems due to a shortage of blood cells, infections and bleeding. It may consist of:
- Blood transfusion.
- Medicines that promote the production of blood cells.
- Medicines that suppress the immune system.
- Low-dose chemotherapy to improve blood cell counts.
- Stem cell transplantation from another person. This is the only potential cure for many types of MDS.
Your provider may try one or more treatments to see what your MDS responds to.
Mikkael Sekeres is a Hematologist Oncology specialist and a Hematologist practicing medicine in Miami, Florida. Dr. Sekeres is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.
Ryotaro Nakamura, M.D.
Ryotaro Nakamura is an Oncologist practicing medicine in Duarte, California. Dr. Nakamura is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Colonoscopy.
The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute
Marcos De Lima is a Hematologist practicing medicine in Columbus, Ohio. Dr. De Lima is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.
The outlook will depend on your type of MDS, genetics of the abnormal cells, and severity of symptoms. Your overall health also may affect your chances of recovery. Many people have stable MDS that does not progress into cancer for years, if ever.
Some people with MDS may develop AML.
MDS complications include:
- Bleeding
- Infections such as pneumonia, gastrointestinal infections, urinary infections
- AML
Contact your provider if you:
- Feel weak and tired most of the time
- Bruise or bleed easily, have bleeding of the gums or frequent nosebleeds
- You notice red or purple spots of bleeding under the skin
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.
Background: Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults. MDS and MDS/MPN can also progress to acute myeloid leukemia. Treatments for these disorders are risky and not always effective. Better treatments are needed.
Published Date: October 21, 2025
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
National Cancer Institute website. Myelodysplastic/myeloproliferative neoplasms treatment (PDQ) - health professional version. www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq. Updated May 14, 2025. Accessed December 2, 2025.
Stone RM. Myelodysplastic syndromes. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 167.
Yabe M, Hasserjian RP. Myelodysplastic syndromes. In: Hsi ED, Wang SA, ed. Hematopathology: Foundations in Diagnostic Pathology. 4th ed. Philadelphia PA: Elsevier; 2026:chap 19.

